A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1309-1315

  Meersma, Gert Jan ^a   Bakker, Marleen ^a   Groen, Harry J M ^a   Van Der Zee, Ate G J ^a   Jensen, Peter Buhl ^b   Giaccone, Guiseppe ^c   De Vries, Elisabeth G E ^a   Smit, Egbert F ^a,c  

^a University Hospital Croningen   (Netherlands)

^b FINSEN LABORATORY   (Denmark)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human tumor specimen; Topoisomerase I gene expression

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; MESSENGER RNA; REAGENT; TOPOTECAN;

ARTICLE; ASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; DEVICE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032997203     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wang JC: DNA topoisomerases. Ann Rev Biochem 54: 665-697, 1985.
2. Pommier Y: Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins. Sem Oncol 23: 3-10, 1996.
3. Li LH, Fraser TJ, Olin EJ, Bhuyan BK: Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650, 1972.
4. Hsiang YH, Likou M Liu F: Arrest of replication forks by drug-stabilized topoisomerase 1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
5. Pommier Y, Tanizawa A Kohn KW. Mechanism of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 29B: 73-92, 1994.
6. Creemers CJ, Lund B, Verweij J: Topoisomerase I inhibitors: topotecan and irinotecan. C ancer Treatm Rev 20: 73-96, 1994.
7. Daney J, Eisenhauer EA: Current perspectjves on camptothecins in cancer treatment. Br J C ancer 74: 327-328, 1996.
8. Andoh T, Ishii K. Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569, 1987.
9. Gupta RS, Gupta R, Eng B, et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404-6410, 1988.
10. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T, Tsuruo T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930, 1990.
11. Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5915-5924, 1990.
12. Tan KB, Mattem MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase 1 and II genes, correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735, 1989.
13. Eng WK, McCabe FL, Tan KB, et al: Development of a stable camptothecin-resistant subline of P388 leukenlia with reduced topoisomerase I content. Mol Pharlllacol 38: 471-480, 1990.
14. Madelaine I, Prost S, Haudin A, Riou G, Lavelle F, Riou JF. Sequential modifications of topoisomerase I activity in a camptothecin resistant cell line established by progressive adaptation. Biochem Pharmacol 45: 339-348, 1993.
15. Sorensen M, Sehested M, Jensen PB: Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase 1-directed drug topotecan. Br J Cancer 72: 399-404, 1995.
16. Chang JY, Dethlefsen LA, Barley LB, Zhou BS, Cheng YC: Characterization of camptothecin-resistant chinese hamster lung cells. Biochem Pharmacol 43: 2443-2452, 1992.
17. Niwa K, Misao R, Hanabayashi T, et al: Semi-quantitative analysis of DNA topoisomerase-l mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jpn J Cancer Res 85: 869-887, 1994.
18. McLeod Hi, Keith WN: Variation in topoisomerase I gene copy number as a mechanism tor intrinsic drug sensitivity. Br J Cancer 74: 508-512, 1996.
19. Tanizawa A, Pommier Y: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F-cell in culture. Cancer Res 52: 1849-1854, 1992.
20. Tamura H, Kohchi C, Yamada R, et al: Molecular cloning of a cDNA of a camptothecin-resistant humall DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 19: 69-75, 1991.
21. Kjeldsen E, Bonven BJ, Andoh T et al: Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263: 3912-3916, 1988.
22. Gromova II, Kjeldsen E, Svejstrup JQ, Alsner J, Christiansen K, Westergaard O: Charac-terization of an altered DNA catalysis of a camptothecin-resistant eukaryotoc topoisomerase I. Nucleic Acids Res 21: 593-600, 1993.
23. Beck WT, Danks MK: Mechanisms of resistance of drugs that inhibit DNA topoisomera-ses. Semin Cancer Biol 2: 235-244, 1991.
24. Withoff S, Smit EF, Meersma GJ, et al: Quantitation of DNA topopoisomerase IIa messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript' titration assay. Lab Invest 71: 61-66, 1994.
25. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1979.
26. De Jong S, Zijlstra JG, de Vries EGE, Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin-phenol reagent. J Biol Chem 193: 265-275, 1951.
28. D'Arpa P, Machlin PS, Ratrie H, Rothfield NF, Cleveland DW, Earnshaw WC. cDNA cloning of human topoisomerase I: catalytic activity of a 67.7-kDa carboxy-terminal fragment. Proc Natl Acad Sci USA 85: 2543-2547, 1988.
29. Kok K, Van den Berg A, Buchhagen DL, Carritt B, Buys CHCM: A PCR-aided transcript titration assay revealing very low expression of a gene at band 3p21 in 33 cell lines derived from all types of lung cancer. Eur J Human Genet 1: 156-163, 1993.
30. Kaufmann SH, Charron M, Burke PJ, Karp JE: Changes in topoisomerase 1 levels and localization during myeloid maturation in vitro and in vivo. Cancer Res 55: 1255-1260, 1995.
31. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
32. Husain I, Mohler JL, Seigler HF, Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration oftumor-type specificity and implications tor cancer chemotherapy. Cancer Res 54: 539-546, 1994.
33. Kowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke, PJ, Cheng Y-C, Grochow LB, Kautmann SH: Phase I and pharmacokinetic study of the topoisome-rase I-inhibitor topotecan in patients with refractary leukemia. J Clin Oncol 12: 2193-2203, 1994.
34. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, Van der Zee AGJ, Kaye SB, Brown R, Keith WN: Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59: 607-611, 1994.
35. Masin JS, Berger SJ, Setrakian S, Stepnick DW, Berger NA: Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laryngoscope 105: 1191-1196, 1995.
36. Van der Zee AGJ, Hollema H, De Jong S, et al: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and atter platinumicyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991,
37. Ciaccone G, Van Arc-Otte J, Scaglotti G et al: Differential expression of DNA topoisomerase genes in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1264: 337-346, 1995.
38. Pommier Y, Leteurte F, Fesen MR, et al. Cellular determinants of sensitivity and resis-tance to DNA lopoisomerase inhibitors. C ancer Invest 12: 530-542, 1994,
39. Plumb JA, McLeod HL, Milrov R Kaye SB, Twelves CJ: Measurement of the topoisome-rase1/DNA/camptothecin cleavable complex as an indicator of drug sensitivity in a panel of lung cancer cell lines. Proc Am Assoc Cancer Res 38: 107 (abstr), 1997.
40. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res 55: 2116-2121, 1995.
41. Conti JA Kemedy NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996.